Envisagenics and Boehringer Ingelheim in $1bn RNA splicing deal
Envisagenics has signed a multi-year research collaboration and option agreement with Boehringer Ingelheim to identify and validate tumour-specific targets derived from alternative RNA splicing, with the goal of developing precision therapies for solid tumours. The New York-based biotech is eligible to receive more than US$1 billion in total payments, comprising an upfront fee, research funding, option fees, and development, regulatory and commercial milestones, plus tiered royalties on future product sales.
Under the terms of the deal, Envisagenics will apply its proprietary SpliceCore platform to identify tumour-selective targets, building on work already completed before the agreement was signed. Boehringer Ingelheim retains the option to take an exclusive licence on selected targets upon successful completion of the research programme, and may deploy those targets across several modalities: antibody-drug conjugates (ADCs), T-cell engagers and multispecific antibodies.
The science behind the deal
Alternative RNA splicing is a post-transcriptional process that dramatically expands the range of proteins a genome can encode. In cancer, splicing is frequently dysregulated, generating tumour-specific protein isoforms that do not appear, or appear at far lower levels, in healthy tissue. These isoforms represent a class of target that conventional gene-centric discovery pipelines cannot easily access, because the distinguishing feature lies at the protein level rather than the DNA sequence.
Envisagenics argues that this makes splicing-derived targets particularly attractive for payloaded modalities such as ADCs, where therapeutic index depends on clear discrimination between tumour and normal cells. Its SpliceCore platform combines large-scale transcriptomics with AI-based prioritisation, screening more than 14 million distinct splicing events to rank candidates by disease specificity, patient prevalence and suitability for downstream drug development.
Maria Luisa Pineda, chief executive and co-founder of Envisagenics, said the collaboration validates the company's view that alternative RNA splicing "represents one of the richest untapped sources of novel disease-specific therapeutic targets across human disease."
Market context and competitive landscape
The collaboration arrives at a moment of intense competition for novel oncology targets. ADCs in particular have become one of the most sought-after modalities in the sector following a string of large-cap acquisitions and approvals over the past three years, driving up demand for differentiated antigen targets that can support best-in-class or first-in-class positioning. Boehringer Ingelheim's willingness to commit to a potentially billion-dollar arrangement for target discovery rights, before any candidate reaches clinical testing, reflects how scarce genuinely tumour-selective surface antigens remain.
A small number of companies are pursuing RNA splicing as a target-identification strategy, including academic spinouts in Europe and the United States working on splice-site neoantigens and cryptic exon targets. Envisagenics is among the more advanced in terms of the scale of its transcriptomics database and the breadth of modalities it is building around splicing-derived hits. Boehringer's own oncology research team has established a track record of pairing novel biologics with precision-selected targets, making the partnership a credible fit on both sides.
Separately, Envisagenics is advancing a wholly owned pipeline that includes ENV-375, a late-stage preclinical antisense oligonucleotide therapy for ALS, suggesting the company is building a bifurcated business: a partnered oncology target engine alongside proprietary neurodegeneration programmes. The near-term milestones investors and observers will watch for are the first nominated targets from the Boehringer collaboration and any IND-enabling activity on the in-house oncology ADC pipeline.